English Deutsch 中文
  • Innovative Solutions
  • Expert Support and Knowledge
  • Reliable Cooperation
Menu Deutsch 中文

Resverlogix and Hepalink Announce a Licensing and Equity Arrangement

Apr. 27, 2015

On Apr 27, 2015, Resverlogix Corp. announced that it has entered into a framework agreement with Shenzhen Hepalink Pharmaceutical. The agreement includes an equity investment of over $40 million and a license of RVX-208 for China, Hong Kong, Taiwan and Macau.

Total sales-based milestones and royalty payments are estimated to be in excess of $400 million.